Shots:
- SystImmune has dosed the first patient with izalontamab brengitecan (iza-bren) in the global P-II/III (IZABRIGHT-Breast01) study for previously untreated TNBC ineligible for anti-PD-(L)1 drugs
- First patient dosing triggered $250M milestone payment to SystImmune under its 2023 deal with BMS, where SystImmune is further eligible to receive additional ~$250M in contingent near-term payments & ~$7.1B in development, regulatory & sales performance milestones
- Iza-bren is also being evaluated in P-I (BL-B01D1-LUNG-101) trial for metastatic or inoperable NSCLC & other solid tumors, P-II/III (IZABRIGHT-Lung01) trial for EGFRm NSCLC & P-II/III (IZABRIGHT-Bladder01) trial for metastatic urothelial cancer
Ref: SystImmune | Image: SystImmune | Press Release
Related News:- SystImmune and BMS’ Izalontamab Brengitecan Secures the US FDA’s Breakthrough Therapy Designation to Treat EGFRm NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
